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Background
Asthma is a problem worldwide, with an estimated 300
million affected individuals. Mometasone being newer
drug has low systemic bioavailability, high glucocorticoid
receptor affinity and modifies inflammatory mediators
involved in the pathogenesis of asthma. Mometasone
significantly improves PFT and symptom control in
patients with asthma when used in combination with
Formoterol. There are very few studies conducted to
assess and compare the safety and efficacy of Mometa-
sone group (Mometasone & Formoterol) versus Flutica-
sone group (Fluticasone & Formoterol). Hence the
present study was undertaken to assess the safety and
efficacy of Mometasone group versus Fluticasone group
using DPI in patients with mild to moderate persistent
asthma and also its effect on symptom control and fre-
quency of rescue medication use.
Methods
The present study was conducted in PMU, Bangalore
during March 2011-2012. 60 patients were recruited in
each arm based on inclusion and exclusion criteria. PFT
was done pre and post bronchodilator with Salbutamol
nebulization with Spirometry. Study medications were
randomized, double blinded and were given for 12weeks
& comparison was done to know safety, efficacy and fre-
quency of rescue medication use before and after treat-
ment in asthmatics. Statistical test -descriptive statistics,
repeated ANOVA, Z- test, t- test.
Results
Out of 60 patients in Fluticasone group, 11 developed
adverse reactions- 4 developed recurrent URTI whereas in
Mometasone group- 7 developed adverse reactions- 2
each developed recurrent URTI & hoarseness of voice.
There was an overall improvement in lung function test
(FVC, FEV1, FEV1/FVC, FEF25-75, PEF) between Mome-
tasone and a Fluticasone group which was statistically sig-
nificant when compared within the group (P=0.001), but
was not significant when compared between the groups
suggesting both are equally efficacious. There was a signifi-
cant reduction in symptoms before and after treatment
within the group, but the reduction was not statistically
significant when compared between the groups suggesting
both are equally efficacious. There was a significant reduc-
tion in dosage of rescue medication used from baseline to
the end of 12weeks in Mometasone group compared to
Fluticasone group (t value= 6.96; P= 0.001).
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Conclusions
Both Mometasone +Formoterol and Fluticasone+ For-
moterol combinations were safe and equally efficacious
in treating asthmatics.
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